Hogan Lovells Publications | Health Alert | 11 September 2017

New Jersey joins wave of states proposing new rules for drug marketing and HCP interactions

Drug manufacturers are once again facing new state limits on marketing and interactions with healthcare providers. Manufacturers should review the new laws and regulations carefully, consider how they might engage with the agencies interpreting the new limits, and begin preparing their own compliance efforts.

Read More: New Jersey Joins Wave of States Proposing New Rules for Drug Marketing and HCP Interactions


Download PDF Back To Listing

Contacts

Helen R. Trilling

Helen R. Trilling

Senior Counsel
Washington, D.C.

Ronald L. Wisor, Jr.

Ronald L. Wisor, Jr.

Partner
Washington, D.C.

Eliza L. Andonova

Eliza L. Andonova

Partner
Washington, D.C.

Contact us
Subscribe